EUVIMEDEUVIMED entdecken
Crossref

A Hypoxia‐Activatable Prodrug for Targeted Combination Therapy of Hepatoma

Hongyu Wang, Tao Zhang, Shaojin Lu, Tingting Sun, Zhigang Xie iD, Xuesi Chen

Advanced Materials · 2026

DOI: 10.1002/adma.202412376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Hongyu Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, P. R. China. Hauptthemen laut MEDLINE: Prodrugs, Liver Neoplasms, Carcinoma, Hepatocellular, Antineoplastic Agents. Die Arbeit nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision medicine is characterized by high accuracy and safety, showing robust superiority and significant potential in clinical applications. Organelle‐targeting therapies are important tactics for precision medicine, allowing for efficient tumor treatment and reduced off‐target toxicity. Herein, a mitochondria‐targeting and hypoxia‐activatable nanoprodrug (POPZ NPs) is prepared. The N‐oxide groups of POPZ NPs can successfully target mitochondria and are reduced to tertiary amines by Cytochrome P450 enzymes (CYP450s), which are highly expressed in hypoxic tumors and located in the inner mitochondrial membranes. Biocompatible POPZ NPs can become cytotoxic and produce type‐I photodynamic activities and enhance photothermal properties after reduction by CYP450s. The tumor‐specific activatable prodrug reveals potent efficacy for tumor elimination without causing systemic toxicity. This work may provide a paradigm for achieving precision medicine as well as more convenient and feasible tumor combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsLiver NeoplasmsCarcinoma, HepatocellularAntineoplastic AgentsHumansAnimalsMiceMitochondriaNanoparticlesCell Line, TumorCytochrome P-450 Enzyme SystemPhotochemotherapyCell Hypoxia

Stichwörter der Autor:innen

N‐oxideactivatable prodrugcombination therapyperylene diimidetumor‐specific

Substanzen

ProdrugsAntineoplastic AgentsCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, P. R. China.
  • School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, Anhui, 230026, P. R. China.
  • Department of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, P. R. China.

ORCID-Profile: Zhigang Xie

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jilin Province

Zitieren

APA

Wang, H., Zhang, T., Lu, S., Sun, T., Xie, Z., & Chen, X. (2026). A Hypoxia‐Activatable Prodrug for Targeted Combination Therapy of Hepatoma. Advanced Materials. https://doi.org/10.1002/adma.202412376

Vancouver

Wang H, Zhang T, Lu S, Sun T, Xie Z, Chen X. A Hypoxia‐Activatable Prodrug for Targeted Combination Therapy of Hepatoma. Advanced Materials. 2026. doi:10.1002/adma.202412376

BibTeX
@article{Wang2026,
  author = {Wang, Hongyu and Zhang, Tao and Lu, Shaojin and Sun, Tingting and Xie, Zhigang and Chen, Xuesi},
  title = {A Hypoxia‐Activatable Prodrug for Targeted Combination Therapy of Hepatoma},
  journal = {Advanced Materials},
  year = {2026},
  doi = {10.1002/adma.202412376}
}
Kostenlos starten →